Fig. 1: UMSCC 103 viability and synergism analysis after treatment with ICI, U0126, and CTX alone or in combination.
From: β2-AR inhibition enhances EGFR antibody efficacy hampering the oxidative stress response machinery
a Viability assay on UMSCC 103 treated with ICI and U0126 at 48 h. The cell death was statistically significant after a single treatment with ICI (10 μM and 25 μM) and U0126 (10 μM); the cytotoxicity increases after treatment with a combination of drugs, with a dose-dependent relationship. b The viability coefficients related to the ICI/U0126 tested concentrations have been plotted in a combination index function to assess the drug’s synergism. The combination of drugs led to a cytotoxic synergic effect at 10 μM ICI + 10 μM U0126, which becomes milder at 25 μM ICI + 10 μM U0126. c Viability assay on UMSCC 103 treated with ICI and CTX at 48 h. The drug combination was very effective in a dose-dependent trend. d Synergism analysis of ICI and CTX cell death mediated, with significant results obtained with several combinations: 10 μM ICI + 20 μM CTX and μM ICI + 20 μM CTX (*P ≤ 0.05; **P ≤ 0.01; ****P ≤ 0.0001 vs. CTR).
